Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.

[1]  M. L. Handoko,et al.  Idiopathic pulmonary arterial hypertension patients with a high H2FPEF-score: Insights from the Amsterdam UMC PAH-cohort. , 2022, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  S. Rosenkranz,et al.  The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study , 2021, European journal of heart failure.

[3]  M. Humbert,et al.  External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry , 2021, European Respiratory Journal.

[4]  S. Rosenkranz,et al.  COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension , 2021, European Respiratory Journal.

[5]  L. Harbaum,et al.  Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  C. Eichstaedt,et al.  Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up , 2020, Respiratory Research.

[7]  J. Barberà,et al.  Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[9]  S. Söderberg,et al.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[10]  B. Kjellström,et al.  Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension , 2018, European Respiratory Journal.

[11]  S. Rosenkranz,et al.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.

[12]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[13]  S. Rosenkranz,et al.  Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. , 2016, Journal of the American College of Cardiology.

[14]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[15]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[16]  S. Rosenkranz,et al.  Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. , 2013, International journal of cardiology.

[17]  J. Lordan,et al.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. , 2012, American journal of respiratory and critical care medicine.

[18]  G. Raskob,et al.  The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. , 2011, Chest.